NATIONAL BREAST CANCER FOUNDATION (NBCF) OUTLINES PINK HORIZON RESEARCH STRATEGY AT BREAST CANCER FORUM Breast Cancer Awareness Month demonstrates integral role of NBCF in research and clinical support
Filmed in Brisbane, Queensland | November 2024
Associate Professor Cleola Anderiesz, Chief Executive Officer of the National Breast Cancer Foundation, leads an organisation dedicated to funding world-class breast cancer research in Australia. The Foundation has a bold vision of achieving zero deaths from breast cancer.
Every October, during Breast Cancer Awareness Month, the foundation uses this time to raise awareness about breast cancer and its impact in Australia. It also emphasises the critical need for funding breast cancer research to improve outcomes.
The National Breast Cancer Foundation collaborates with researchers, providing essential funding while also engaging them, clinicians, and consumers to establish research priorities.
Australian Health Journal met with Assoc Prof Anderiesz to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
Recently, Assoc Professor Anderiesz presented at the Public Breast Cancer Research Forum hosted by The University of Queensland and the Translational Research Institute, where she highlighted the accomplishments of the National Breast Cancer Foundation over the past 30 years. During this time, the Foundation has invested over $200 million into more than 600 research projects across Australia, supporting 1,800 researchers at 120 institutes to advance impactful breast cancer research.
Professor Anderiesz believes it is essential for all members of the breast cancer community to consistently seek opportunities to raise awareness about the disease’s impact. This awareness should extend beyond October and include efforts to inform primary care physicians and specialists. Additionally, there is a need to promote groundbreaking research and advocate for changes in policy and care to improve outcomes for individuals affected by breast cancer.
-
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
-
Spinal implant technology eyes global opportunity
Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
-
Occupational therapy creates profound impacts on client and patient lives
Margeaux Bartholomew-Carle is an Adelaide based registered Occupational Therapist and the Founder and CEO of Ardant.
Throughout her career, Margeaux has worked in various settings, including aged care, disability, assistive technology, prescription, and mental health. This diverse experience has deepened her understanding of the different needs among client groups.
